Microsoft Word - NET CTPM Executive Summary.doc - Carcinoid - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2014-06-30 21:58:27 Lung cancer Bevacizumab Carcinoid Sunitinib Temozolomide Everolimus Medicine Oncology Neuroendocrine tumor		Microsoft Word - NET CTPM Executive Summary.doc Add to Reading List Source URL: www.cancer.gov Download Document from Source Website File Size: 35,35 KB Share Document on Facebook

	PDF Document DocID: 1xrdj - View Document
	ORIGINAL ARTICLE Clinical Value of Monitoring Plasma Octreotide Levels During Chronic Octreotide Long-Acting Repeatable Therapy in Carcinoid Patients Eugene A. Woltering, MD, FACS,* Vergilio A. Salvo, MD,* Thomas M. O_D DocID: 1rlNJ - View Document
	JOBNAME: pan 31#PAGE: 1 OUTPUT: Wednesday October 19 08:24:lww/panMPA200087 ORIGINAL ARTICLE Effect of Octreotide LAR Dose and Weight on Octreotide DocID: 1qMJM - View Document
	ORIGINAL ARTICLE Validation of Serum Versus Plasma Measurements of Chromogranin A Levels in Patients With Carcinoid Tumors Lack of Correlation Between Absolute Chromogranin A Levels and Symptom Frequency DocID: 1p1DF - View Document
	ORIGINAL ARTICLE Development of a Highly Sensitive and Specific Carboxy-Terminal Human Pancreastatin Assay to Monitor Neuroendocrine Tumor Behavior Thomas M. O’Dorisio, MD,* Siegfried R. Krutzik, PhD,Þ Eugene A. Wolt DocID: 1oIE2 - View Document